56results about How to "Less antigen" patented technology

The invention relates to an immunological adjuvant containing fucosan sulfate and application of the immunological adjuvant. The technical problems that at present, the kinds of immunological adjuvants are few, side effects cannot be avoided, and a great number of vaccines need to be provided when infectious diseases break out are solved. The immunological adjuvant consists of the following components in mass ratio: fucosan sulfate, ginsenoside and the rest of carriers, wherein the carriers consist of the following components in mass ratio: an emulsifying agent, an emulsifying auxiliary agent, oil phase and aqueous phase. The immunological adjuvant can be widely used in the preparation field of vaccines.

The invention provides a taxus polysaccharide immunologic adjuvant and an influenza vaccine containing the same. The taxus polysaccharide immunologic adjuvant consists of the following components in percentage by mass: 0.001 to 100 percent of taxus polysaccharide and 0 to 99.999 percent of carrier. A mass ratio of the taxus polysaccharide immunologic adjuvant to hemagglutinin of the influenza vaccine is 50 to 183,500. The taxus polysaccharide is a natural substance extracted from branches of taxus; when the taxus polysaccharide is used as the immunologic adjuvant, applicable experiment results are obtained, and the taxus polysaccharide has high safety and small side effect. The influenza vaccine containing the taxus polysaccharide immunologic adjuvant is easy and convenient to prepare, the quality of the vaccine is easy to control, the immunogenicity of the vaccine can be better improved, and the dosage of antigen of the vaccine is greatly reduced; experiments prove that the dosage ofthe antigen of the vaccine, which takes the taxus polysaccharide as the adjuvant, is only half or lower than half of the dosage of the antigen of the vaccine, which takes aluminum hydroxide as the adjuvant, but the immune protective effect is the same.

An improved assay is described where a surface is provided with immobilized anti-Ig antibodies rather than antigen and where specific antibody-secreting cells (ASC) are detected using soluble antigen probes containing one of several possible labels. The method gives improved sensitivity with less background and is also more representative because antigen binding does not employ immobilized antigen. The assay is particularly effective for measuring antibody secreting cells against HIV, for determining whether an infection is acute as opposed to old or latent, for mapping epitopes and for measuring for ASCs against different antigens in the same reaction.

The invention discloses a foot and mouth disease virus structural protein antibody enzyme-linked immunosorbent assay kit. The kit comprises an enzyme-linked reaction plate coated by foot and mouth disease virus structural protein VP1 antigenic epitope polypeptides, and an enzyme-labeled antibody. The foot and mouth disease virus structural protein VP1 antigenic epitope polypeptides are a polypeptide represented by the sequence 1 in the sequence list and a polypeptide represented by the sequence 2 in the sequence list. According to the kit, the reaction plate coated by chemically synthesized VP1 antigenic peptide, antigen dose is low, sensitivity is high, and specificity is high. With the kit, whether foot and mouth disease virus infection exists can be highly efficiently detected. The kit provided by the invention has good specificity, high sensitivity, high efficiency, and good market prospect.

The efficacy of rabies vaccines can be enhanced by adjuvanting rabies virus immunogens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. The rabies virus immunogen can also be adsorbed to the metal salt.

The invention provides a method for preparing nasal-spray type influenza virus vaccine containing CpG ODN and poly I:G adjuvant, which belongs to the technical field of biology. The method comprises the following steps: adopting chicken embryo to culture proliferative influenza virus; obtaining purified influenza virus through ultrafiltration concentration and column chromatography; obtaining influenza vaccine stock solution through lysis; and proportioning the influenza vaccine stock solution of a required type to CpG ODN adjuvant or I:G adjuvant. The invention provides the method for preparing novel nasal-spray type influenza virus vaccine, which can reduce the amount of influenza virus antigen, provides convenience for immunization and vaccination, and is suitable for rapidly improving the capacity of supplying influenza vaccine under threat of global pandemic influenza.

The invention discloses a nasal spray immunity flu polyvalent vaccine and a preparing method. Flu quadrivalence (H1N1, H3N2, H5N1, B type) or polyvalent attenuated live vaccine is used for immunoprophylaxis through nose spraying, popular flu and highly pathogenic avian influenza can be prevented safely and efficiently.

The invention discloses a nonstructural protein antibody ELISA (enzyme-linked immunosorbent assay) kit for a porcine foot-and-mouth disease virus. The kit comprises a foot-and-mouth disease virus nonstructural protein epitope polypeptide coated enzyme-linked reaction plate and an enzyme labeled antibody; foot-and-mouth disease virus nonstructural protein epitope polypeptides are a polypeptide shown as sequence 1, a polypeptide shown as sequence 2, a polypeptide shown as sequence 3 and a polypeptide shown as sequence 4 in a sequence table. According to the kit, a chemically synthesized nonstructural protein antigen peptide is used for coating the reaction plate, antigen dosage is small, sensitivity and specificity are high, and the presence of foot-and-mouth disease virus infection can be effectively detected. The kit provided by the invention has good specificity, sensitivity and high efficiency, and has good market prospect.

The invention relates to a preparation method of antiserum, and in particular to a preparation method and application of Koi herpes virus antiserum. The preparation method comprises the following steps: selecting healthy Koi as an experimental animal, collecting purified Koi herpes virus antigens, subcutaneously injecting at multiple points of the back of the Koi, when a serum titer reaches a peak value, sampling a great amount of blood from heart or caudal veins, separating serum, measuring a titer, split charging, freezing, and storing. The obtained Koi herpes virus antiserum is used for detecting a KHV (Koi herpes virus) antigen and can be used as positive serum of the KHV antibody detection method. According to the preparation method of the Koi herpes virus antiserum, a preparation method of Koi KHV resistant antiserum is established, the high-titer antiserum is obtained, and the obtained antiserum can be used for detecting the KHV antigen in methods such as IFAT, ELISA and the like and can be used as the positive serum to detect the KHV antibody. A programmed antiserum preparation method is provided for performing the KHV or KHV antibody immunology diagnosis in China, and a finished product immunology diagnosis reagent can be provided.

Disclosed is an antigen-adjuvant microparticle complex which comprises adjuvant microparticles and an antigen encapsulated in the adjuvant microparticles, wherein each of the adjuvant microparticles comprises an amphipathic polymer which has a poly(hydroxy acid) as a hydrophobic segment. Also disclosed is an immunogenic composition which contains particles conjugated with the complex as an active ingredient. The complex or the immunogenic composition can induce a high immune response to a small quantity of an antigen or can induce a high immune response to an antigen by a few frequencies of administration, and is therefore useful as a vaccine that is effective for the treatment and prevention of infectious diseases, cancer and others.

The invention relates to a turtle shell immunoadjuvant and an influenza vaccine containing the immunoadjuvant; the turtle shell immunoadjuvant comprises the following ingredients in percentage by weight: 0.001-100% of turtle shell extractive and 0-99.999% of carriers. The composition of the influenza vaccine containing the turtle shell immunoadjuvant is as follows: the mass ratio of the turtle shell immunoadjuvant to the influenza vaccine hemagglutinin is 50-180050. The turtle shell immunoadjuvant in the invention has a good immunoadjuvant effect and has an effect of effectively preventing diseases in human and animal vaccine. The turtle shell extractive is used as the immunoadjuvant of the influenza vaccine; compared with the traditional aluminum hydroxide immunoadjuvant, the turtle shell immunoadjuvant has high using safety and small byeffect, can well improve the original nature of the influenza vaccine; in the process of preparing the influenza vaccine, the method is simple, economic and environment friendly and convenient; the method easily controls the mass, greatly reduces the dosage of the influenza vaccine antigen and satisfies the immunity demand when occurring the epidemic influenza.

The invention relates to an application of chitosan in avian vaccine composition preparation. An avian vaccine composition comprises newcastle disease inactivation virus or avian influenza inactivation virus and other avian vaccine antigens, and a chitosan solution, wherein the avian vaccine comprises a water phase and an oil phase, the chitosan solution is in the water phase, and a concentration of the chitosan solution is 0.1-0.5% W/V, most preferably 0.2-0.5% W/V. According to the avian vaccine composition, the amount of the antigen is low so as to reduce side reactions of the avian vaccine and reduce avian vaccine cost, such that the avian vaccine composition such as newcastle disease vaccines or avian influenza vaccines and the like are suitable for industrial production.

The invention belongs to the technical field of monoclonal antibodies and particularly relates to a preparation method of a mouse anti-human SAA monoclonal antibody. The method comprises the followingsteps of (1) antigen preparation; (2) animal immunization; (3) cell fusion, wherein preparation work including preparation of spleen cells and preparation of a feeding layer is carried out before fusion; (4) screening and cloning of hybridoma cells; (5) expanded production of the monoclonal antibody; (6) determination of the type, subtype and ascites titer of the monoclonal antibody. In step 2, amulti-point injection mode is adopted during first immunization and second immunization, and an emulsified antigen is used and injected into the intradermal cells, foot pads and the abdominal cavityseparately; at the same time, shock immunization is performed once three days before fusion. According to the preparation method, a multi-point combined immunization mode and a shock immunization modeare adopted, the antigen dosage is low, the process is simple, little damage is caused to mice, and the immunization effect is good. The preparation process of the feeding layer is optimized, the growth of the hybridoma cells is promoted, and the cell fusion rate and the positive rate are increased.

The invention discloses a brucellosis vaccine needle-free injection system and application. The brucellosis vaccine needle-free injection system comprises a container filled with a brucellosis vaccine and a readable carrier. Content recorded in the readable carrier includes that needle-free injection dosage of the brucellosis vaccine is not larger than the standard dosage of the brucellosis vaccine. Experiments prove that when a needle-free injection ampoule and a needle-free syringe are combined and used for immunization, the antigen dosage only accounts for part of a traditional intramuscular injection antigen dosage, and the same or better immune effect can be achieved. It is further indicated that a needle-free immune mode is an ideal strategy capable of being selected by the brucellosis immunization vaccine.

The invention relates to the field of biological detection, and discloses a Kratom antigen as well as a preparation method and application of the Kratom antigen, the Mitragynine complete antigen and the 7-hydroxy Mitragynine complete antigen completely reserve active groups in molecular structures, so that the Kratom antigen has relatively strong specificity and relatively high sensitivity.